[1]盛红枫,张培祥,张魁,等.自然铜合方在股骨干骨折术后骨不连脾肾两虚夹瘀证治疗中的应用[J].中医正骨,2019,31(12):1-9.
　SHENG Hongfeng,ZHANG Peixiang,ZHANG Kui,et al.Application of pyritum integrated decoction in treatment of spleen-kidney-deficiency-blood-stasis-type postoperative nonunion of femoral shaft fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(12):1-9.
点击复制

自然铜合方在股骨干骨折术后骨不连脾肾两虚夹瘀证治疗中的应用()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第31卷
期数:
2019年12期
页码:
1-9
栏目:
临床研究
出版日期:
2019-12-20

文章信息/Info

Title:
Application of pyritum integrated decoction in treatment of spleen-kidney-deficiency-blood-stasis-type postoperative nonunion of femoral shaft fractures
作者:
盛红枫; 张培祥; 张魁; 陆建伟
(浙江省立同德医院,浙江 杭州 310012)
Author(s):
SHENG Hongfeng; ZHANG Peixiang; ZHANG Kui; LU Jianwei
Tongde Hospital of Zhejiang Province,Hangzhou 310012,Zhejiang,China
关键词:
股骨骨折;  手术后并发症;  骨折; 不愈合;  脾虚;  肾虚;  血瘀;  自然铜;  骨密度;  骨钙素;  骨保护素;  Ⅰ型胶原N末端肽;  抗酒石酸酸性磷酸酶5b
Keywords:
femoral fractures;  postoperative complications;  fractures; ununited;  spleen deficiency;  kidney deficiency;  blood stasis;  pyritum;  bone density;  osteocalcin;  osteoprotegerin;  collagen typeⅠN-telepeptide;  tartrate resistant acid phosphatase-5b
摘要:
目的:探讨自然铜合方在股骨干骨折术后骨不连脾肾两虚夹瘀证治疗中的应用价值。方法:回顾性分析2010年1月至2017年6月40例股骨干骨折交锁髓内钉内固定术后骨不连脾肾两虚夹瘀证患者的病例资料,自然铜合方组和碳酸钙D3组各20例。2组患者采用原内固定方式重新固定骨折并在骨折端植骨后,均予以碳酸钙D3片口服,每次2片,每日1次; 自然铜合方组患者在此基础上予以自然铜合方水煎服,每日1剂,早晚各1次。治疗9个月后,检测2组患者骨密度,并参照《骨科学》中骨折临床愈合评价标准评价疗效。分别于治疗前和治疗3个月后、6个月后、9个月后,检测血清骨钙素(bone glaprotein,BGP)、骨保护素(osteoprotegerin,OPG)、Ⅰ型胶原N末端肽(collagen typeⅠN-telepeptide,NTX)、抗酒石酸酸性磷酸酶5b(tartrate resistant acid phosphatase-5b,TRACP-5b)水平观察骨代谢情况,检测血清谷草转氨酶(aspartate aminotransferase,AST)、谷丙转氨酶(alanine aminotransferase,ALT)、肌酐(creatinine,Cr)水平评价肝肾功能。结果:①骨密度和临床疗效。治疗前2组患者骨密度比较,差异无统计学意义[(0.91±0.06)g·cm-2,(0.93±0.05)g·cm-2,t=4.109,P=0.197]; 治疗9个月后,2组患者骨密度均比治疗前提高[(0.91±0.06)g·cm-2,(1.38±0.04)g·cm-2,t=25.900,P=0.000;(0.93±0.05)g·cm-2,(1.07±0.03)g·cm-2,t=8.994,P=0.000],且自然铜合方组骨密度高于碳酸钙D3组(t=26.684,P=0.000)。自然铜合方组骨折临床愈合13例、好转6例、无效1例,碳酸钙D3组骨折临床愈合6例、好转8例、无效6例,自然铜合方组临床疗效优于碳酸钙D3组(Z=-2.472,P=0.013)。②血清BGP水平。时间因素和分组因素存在交互效应(F=3.343,P=0.022); 2组患者血清BGP水平总体比较,差异有统计学意义,即存在分组效应(F=8.398,P=0.006); 治疗前后不同时间点之间患者血清BGP水平的差异有统计学意义,即存在时间效应(F=64.142,P=0.000); 2组患者血清BGP水平随时间变化总体上均呈上升趋势,但2组的上升趋势不完全一致; 治疗前和治疗3个月后,2组患者血清BGP水平比较,差异均无统计学意义[(4.47±0.18)μg·L-1,(4.55±0.28)μg·L-1,t=-1.063,P=0.295;(4.96±0.28)μg·L-1,(4.80±0.31)μg·L-1,t=1.605,P=0.117]; 治疗6个月后和治疗9个月后,自然铜合方组血清BGP水平均高于碳酸钙D3组[(5.19±0.24)μg·L-1,(4.98±0.29)μg·L-1,t=2.437,P=0.020;(5.42±0.24)μg·L-1,(5.15±0.31)μg·L-1,t=3.054,P=0.004]。③血清OPG水平。时间因素和分组因素存在交互效应(F=26.320,P=0.000); 2组患者血清OPG水平总体比较,差异有统计学意义,即存在分组效应(F=118.438,P=0.000); 治疗前后不同时间点之间患者血清OPG水平的差异有统计学意义,即存在时间效应(F=136.254,P=0.000); 2组患者血清OPG水平随时间变化总体上均呈上升趋势,但2组的上升趋势不完全一致; 治疗前和治疗3个月后,2组患者血清OPG水平比较,差异均无统计学意义[(5.98±0.26)μg·L-1,(5.85±0.22)μg·L-1,t=1.677,P=0.102;(6.47±0.27)μg·L-1,(6.37±0.22)μg·L-1,t=1.314,P=0.197]; 治疗6个月后和治疗9个月后,自然铜合方组血清OPG水平均高于碳酸钙D3组[(7.14±0.23)μg·L-1,(6.41±0.24)μg·L-1,t=10.053,P=0.000;(7.34±0.29)μg·L-1,(6.50±0.25)μg·L-1,t=9.861,P=0.000]。④血清NTX水平。时间因素和分组因素存在交互效应(F=3.549,P=0.017); 2组患者血清NTX水平总体比较,差异有统计学意义,即存在分组效应(F=10.885,P=0.002); 治疗前后不同时间点之间患者血清NTX水平的差异有统计学意义,即存在时间效应(F=163.624,P=0.000); 2组患者血清NTX水平随时间变化总体上均呈降低趋势,但2组的降低趋势不完全一致; 治疗前和治疗3个月后,2组患者血清NTX水平比较,差异均无统计学意义[(4.49±0.23)μg·L-1,(4.35±0.35)μg·L-1,t=1.422,P=0.163;(4.25±0.29)μg·L-1,(4.29±0.31)μg·L-1,t=-0.421,P=0.676]; 治疗6个月后和治疗9个月后,自然铜合方组血清NTX水平均高于碳酸钙D3组[(3.46±0.44)μg·L-1,(3.10±0.29)μg·L-1,t=3.051,P=0.004;(3.47±0.33)μg·L-1,(3.18±0.24)μg·L-1,t=3.250,P=0.002]。⑤血清TRACP-5b水平。时间因素和分组因素存在交互效应(F=9.164,P=0.000); 2组患者血清TRACP-5b水平总体比较,差异有统计学意义,即存在分组效应(F=32.210,P=0.000); 治疗前后不同时间点之间患者血清TRACP-5b水平的差异有统计学意义,即存在时间效应(F=353.626,P=0.000); 2组患者血清TRACP-5b水平随时间变化总体上均呈降低趋势,但2组的降低趋势不完全一致; 治疗前,2组患者血清TRACP-5b水平比较,差异无统计学意义[(8.40±0.35)μg·L-1,(8.33±0.32)μg·L-1,t=0.747,P=0.459]; 治疗3个月后、6个月后和9个月后,自然铜合方组血清TRACP-5b水平均低于碳酸钙D3组[(6.39±0.32)μg·L-1,(6.69±0.46)μg·L-1,t=-2.392,P=0.022;(6.13±0.32)μg·L-1,(6.78±0.30)μg·L-1,t=-6.605,P=0.000;(6.08±0.25)μg·L-1,(6.56±0.36)μg·L-1,t=-4.907,P=0.000]。⑥血清AST、ALT、Cr水平。时间因素和分组因素均不存在交互效应(F=2.629,P=0.054; F=0.203,P=0.894; F=0.272,P=0.845); 治疗前,自然铜合方组血清AST水平低于碳酸钙D3组[(18.46±6.83)μmol·L-1,(23.29±6.99)μmol·L-1,t=-2.210,P=0.033],但2组患者血清AST、ALT、Cr水平总体比较,组间差异均无统计学意义,即均不存在分组效应(F=1.364,P=0.250; F=1.328,P=0.256; F=0.468,P=0.498); 治疗前后不同时间点之间患者血清AST、ALT、Cr水平的差异均无统计学意义,即均不存在时间效应(F=0.786,P=0.504; F=0.582,P=0.628; F=0.986,P=0.402)。结论:对于股骨干骨折术后骨不连脾肾两虚夹瘀证患者,在二次固定并植骨的基础上,口服自然铜合方和碳酸钙D3片比单纯口服碳酸钙D3片,在调节骨代谢、增加骨密度、促进骨折愈合方面更有优势,且二者对患者肝肾功能的影响相当。
Abstract:
Objective:To explore the applied values of pyritum integrated decoction in treatment of spleen-kidney-deficiency-blood-stasis-type postoperative nonunion of femoral shaft fractures.Methods:The medical records of 40 patients with spleen-kidney-deficiency-blood-stasis-type fracture nonunion after internal fixation with interlocking intramedullary nail for treatment of femoral shaft fractures from January 2010 to June 2017 were analyzed retrospectively.Twenty patients were treated with pyritum integrated decoction(pyritum integrated decoction group),while the others were treated with calcium carbonate D3(calcium carbonate D3 group).All patients in the 2 groups were treated with oral applications of calcium carbonate D3 tablets after the fractures were refixed with initial internal fixation method and bone grafting were conducted at the broken ends of fractured femoral shaft,once a day,2 tablets at a time.Moreover,the patients in pyritum integrated decoction group were treated with pyritum integrated decoction,one dose a day in the morning and evening respectively.After 9-month treatment,the bone mineral density(BMD)was measured in the 2 groups,and the curative effects were evaluated according to clinical fracture healing evaluation standard which was extracted from ORTHOPAEDICS.The serum levels of bone glaprotein(BGP),osteoprotegerin(OPG),collagen typeⅠN-telepeptide(NTX)and tartrate resistant acid phosphatase-5b(TRACP-5b)were detected for evaluating bone metabolism and the serum levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT)and creatinine(Cr)were detected for evaluating functions of liver and kidney before the treatment and after 3-,6- and 9-month treatment respectively.Results:There was no statistical difference in the BMD between the 2 groups before the treatment(0.91+/-0.06 vs 0.93+/-0.05 g/cm(2),t=4.109,P=0.197).The BMD increased in the 2 groups after 9-month treatment compared to pre-treatment(0.91+/-0.06 vs 1.38+/-0.04 g/cm(2),t=25.900,P=0.000; 0.93+/-0.05 vs 1.07+/-0.03 g/cm(2),t=8.994,P=0.000),and the BMD was higher in pyritum integrated decoction group compared to calcium carbonate D3 group(t=26.684,P=0.000).Thirteen patients healed,6 good and 1 poor in pyritum integrated decoction group; while 6 patients healed,8 good and 6 poor in calcium carbonate D3 group.The pyritum integrated decoction group surpassed calcium carbonate D3 group in clinical curative effects(Z=-2.472,P=0.013).There was interaction between time factor and group factor in serum level of BGP(F=3.343,P=0.022).There was statistical difference in serum level of BGP between the 2 groups in general,in other words,there was group effect(F=8.398,P=0.006).There was statistical difference in serum level of BGP between different timepoints before and after the treatment,in other words,there was time effect(F=64.142,P=0.000).The serum level of BGP presented a time-dependent increasing trend in the 2 groups in general,while the 2 groups were inconsistent with each other in the variation tendency.There was no statistical difference in serum level of BGP between the 2 groups before the treatment and after 3-month treatment(4.47+/-0.18 vs 4.55+/-0.28 μg/L,t=-1.063,P=0.295; 4.96+/-0.28 vs 4.80+/-0.31 μg/L,t=1.605,P=0.117).The serum levels of BGP were higher in pyritum integrated decoction group compared to calcium carbonate D3 group after 6- and 9-month treatment(5.19+/-0.24 vs 4.98+/-0.29 μg/L,t=2.437,P=0.020; 5.42+/-0.24 vs 5.15+/-0.31 μg/L,t=3.054,P=0.004).There was interaction between time factor and group factor in serum level of OPG(F=26.320,P=0.000).There was statistical difference in serum level of OPG between the 2 groups in general,in other words,there was group effect(F=118.438,P=0.000).There was statistical difference in serum level of OPG between different timepoints before and after the treatment,in other words,there was time effect(F=136.254,P=0.000).The serum level of OPG presented a time-dependent increasing trend in the 2 groups in general,while the 2 groups were inconsistent with each other in the variation tendency.There was no statistical difference in serum level of OPG between the 2 groups before the treatment and after 3-month treatment(5.98+/-0.26 vs 5.85+/-0.22 μg/L,t=1.677,P=0.102; 6.47+/-0.27 vs 6.37+/-0.22 μg/L,t=1.314,P=0.197).The serum levels of OPG were higher in pyritum integrated decoction group compared to calcium carbonate D3 group after 6- and 9-month treatment(7.14+/-0.23 vs 6.41+/-0.24 μg/L,t=10.053,P=0.000; 7.34+/-0.29 vs 6.50+/-0.25 μg/L,t=9.861,P=0.000).There was interaction between time factor and group factor in serum level of NTX(F=3.549,P=0.017).There was statistical difference in serum level of NTX between the 2 groups in general,in other words,there was group effect(F=10.885,P=0.002).There was statistical difference in serum level of NTX between different timepoints before and after the treatment,in other words,there was time effect(F=163.624,P=0.000).The serum level of NTX presented a time-dependent decreasing trend in the 2 groups in general,while the 2 groups were inconsistent with each other in the variation tendency.There was no statistical difference in serum level of NTX between the 2 groups before the treatment and after 3-month treatment(4.49+/-0.23 vs 4.35+/-0.35 μg/L,t=1.422,P=0.163; 4.25+/-0.29 vs 4.29+/-0.31 μg/L,t=-0.421,P=0.676).The serum levels of NTX were higher in pyritum integrated decoction group compared to calcium carbonate D3 group after 6- and 9-month treatment(3.46+/-0.44 vs 3.10+/-0.29 μg/L,t=3.051,P=0.004; 3.47+/-0.33 vs 3.18+/-0.24 μg/L,t=3.250,P=0.002).There was interaction between time factor and group factor in serum level of TRACP-5b(F=9.164,P=0.000).There was statistical difference in serum level of TRACP-5b between the 2 groups in general,in other words,there was group effect(F=32.210,P=0.000).There was statistical difference in serum level of TRACP-5b between different timepoints before and after the treatment,in other words,there was time effect(F=353.626,P=0.000).The serum level of TRACP-5b presented a time-dependent decreasing trend in the 2 groups in general,while the 2 groups were inconsistent with each other in the variation tendency.There was no statistical difference in serum level of TRACP-5b between the 2 groups before the treatment(8.40+/-0.35 vs 8.33+/-0.32 μg/L,t=0.747,P=0.459).The serum levels of TRACP-5b were lower in pyritum integrated decoction group compared to calcium carbonate D3 group after 3-,6- and 9-month treatment(6.39+/-0.32 vs 6.69+/-0.46 μg/L,t=-2.392,P=0.022; 6.13+/-0.32 vs 6.78+/-0.30 μg/L,t=-6.605,P=0.000; 6.08+/-0.25 vs 6.56+/-0.36 μg/L,t=-4.907,P=0.000).There was no interaction between time factor and group factor in serum levels of AST,ALT and Cr(F=2.629,P=0.054; F=0.203,P=0.894; F=0.272,P=0.845).The serum level of AST was lower in pyritum integrated decoction group compared to calcium carbonate D3 group before the treatment(18.46+/-6.83 vs 23.29+/-6.99 μmol/L,t=-2.210,P=0.033),while there was no statistical difference in serum levels of AST,ALT and Cr between the 2 groups in general,in other words,there was no group effect(F=1.364,P=0.250; F=1.328,P=0.256; F=0.468,P=0.498).There was no statistical difference in serum levels of AST,ALT and Cr between different timepoints before and after the treatment,in other words,there was no time effect(F=0.786,P=0.504; F=0.582,P=0.628; F=0.986,P=0.402).Conclusion:For patients with spleen-kidney-deficiency-blood-stasis-type postoperative nonunion of femoral shaft fractures,oral applications of pyritum integrated decoction and calcium carbonate D3 tablets is better than oral application of calcium carbonate D3 tablets in regulating bone metabolism,increasing bone density and promoting fracture healing,and they have similar effects on liver and kidney function.

参考文献/References:

[1] CALORI G M,ALBISETTI W,AGUS A,et al.Risk factors contributing to fracture non-unions[J].Injury,2007,38(Suppl 2):S11-18. [2] GELALIS I D,POLITIS A N,ARNAOUTOGLOU C M,et al.Diagnostic and treatment modalities in nonunions of the femoral shaft:a review[J].Injury,2012,43(7):980-988. [3] 郑筱萸.中药新药临床研究指导原则:试行[M].北京:中国医药科技出版社,2002:361-390. [4] 裴福兴,陈安民.骨科学[M].北京:人民卫生出版社,2016:82-89. 中医正骨2019年12月第31卷第12期 J Trad Chin Orthop Trauma,2019,Vol.31,No.12(总889) (总890)中医正骨2019年12月第31卷第12期 J Trad Chin Orthop Trauma,2019,Vol.31,No.12 [5] 孙艳红,韩正云,李建民.补肾健骨汤对绝经后骨质疏松症患者骨密度及骨代谢指标的影响[J].河北中医药学报,2017,32(1):14-16. [6] 韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7-11. [7] 余斌.骨不连的认识与处理[J].中华创伤骨科杂志,2018,20(10): 829-830. [8] 刘毅峰.自拟补肾活血方治疗创伤骨折后骨质疏松症60例[J].环球中医药,2014,7(7):537-539. [9] 龚健,罗检成,杨迪,等.骨折后骨不连的相关因素分析[J].中国伤残医学,2016,24(20):70-71. [10] 薛俊民,李建林,李铁军.股骨骨折术后骨不连的危险因素分析[J].宁夏医科大学学报,2018,40(5):586-589. [11] 吕志宇.老年髋部骨折手术后二次骨折患者的骨代谢分析[J].浙江创伤外科,2015,20(5):883-886. [12] THIRUNAVUKKARASU K,MILES R R,HALLADAY D L,et al.Stimulation of osteoprotegerin(OPG)gene expression by transforming growth factor-beta(TGF-beta).Mapping of the OPG promoter region that mediates TGF-beta effects[J].J Biol Chem,2001,276(39):36241-36250. [13] MIZRAK S,TURAN V,INAN S,et al.Effect of nicotine on RANKL and OPG and bone mineral density[J].J Invest Surg,2014,27(6):327-331. [14] MIN H,MORONY S,SAROSI I,et al.Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis[J].J Exp Med,2000,192(4):463-474. [15] 王宵光.三花接骨散等对四肢骨折患者血清BGP水平的影响[J].中医正骨,2004,16(1):4-5. [16] 林坚平,沈宁江,史占军,等.NTX在兔实验性骨不连早期诊断中的作用[J].实用骨科杂志,2015,21(9):812-816. [17] 徐爱贤,高学媛.磁与自然铜促进骨折愈合的实验研究[J].山东中医杂志,2008,8(8):558-560. [18] 刘震,回娜,魏玉良,等.早-中-晚三期辨治Pilon骨折微创(有限内+超踝外固定)术后90例临床观察[J].实用中医内科杂志,2016,30(10):54-55. [19] 隋晓辉,金成辉,张丽.分期辨证联合切开复位内固定术治疗新鲜闭合性跟骨关节内骨折60例临床观察[J].实用中医内科杂志,2014,28(3):61-63. [20] 曹照文,袁拯忠,叶人,等.自然铜和鹿衔草对裸鼠肺癌骨转移的抑制作用[J].中华中医药学刊,2012,30(1):137-139. [21] 陈迪坤,徐展望.经皮椎体成形术联合中药治疗骨质疏松性胸腰椎压缩骨折临床观察[J].西部中医药,2013,26(11):93-95. [22] 苏志伟,郑志永,金军.补肾方治疗创伤骨折后骨质疏松症的临床观察[J].河北中医,2010,32(10):1466-1467. [23] 王少君,李艳,刘红,等.中医理论对骨质疏松症发病机制的认识[J].世界中医药,2013,8(9):1044-1048. [24] 李兆勇,杨少锋,张晨阳.补肾活血方联合经皮椎体强化术治疗骨质疏松性椎体压缩骨折的系统评价[J].中医正骨,2019,31(3):28-32. [25] 王德,刘森,李阳,等.补肾活血方联合骨搬移治疗胫骨中下段骨折不愈合疗效观察[J].河北中医,2019,41(1):83-86.

相似文献/References:

[1]王 强.胫腓下联合骨牵引配合手法整复小夹板外固定治疗 儿童闭合移位性股骨干骨折[J].中医正骨,2015,27(10):15.
[2]邓红敏,刘志诚.转子间斜行截骨结合股骨近端防旋髓内钉固定治疗 股骨近端骨折术后髋内翻畸形[J].中医正骨,2015,27(10):17.
[3]李翰林,童培建.利福平联合用药配合保留假体清创治疗 人工关节置换术后早期感染及低毒性感染[J].中医正骨,2015,27(09):56.
[4]魏岚,吴晶晶,康永生.自我效能感理论在股骨干骨折围手术期护理中的应用[J].中医正骨,2015,27(09):77.
[5]阮朝阳,曾强华,朱群威.口服消栓口服液和甲钴胺胶囊治疗腰椎间盘突出症 经皮椎间孔镜术后下肢残留神经症状[J].中医正骨,2015,27(12):71.
[6]邵礼晖,潘浩.Coflex棘突间动态稳定系统治疗腰椎退变性疾病40例[J].中医正骨,2015,27(02):37.
[7]杨少辉,许红霞,邢健昆.正骨伸筋胶囊在膝关节周围骨折术后康复中的应用[J].中医正骨,2015,27(02):43.
[8]张振南,王爱国,白玉,等.保留原钉的单皮质锁定加压钢板内固定配合植骨治疗 股骨干骨折髓内钉固定术后骨折不愈合[J].中医正骨,2015,27(05):40.
[9]谭新欢,聂伟志,朱育林,等.跟骨骨折微创治疗的研究进展[J].中医正骨,2015,27(05):73.
[10]汤金城,谭旭仪,成传德.前外侧切口可吸收螺钉内固定治疗Hoffa骨折[J].中医正骨,2015,27(03):44.
[11]张镇,沈金虎,惠正广,等.股骨远端微创内固定系统内固定配合抗骨质疏松药物口服治疗股骨近端防旋髓内钉内固定术后同侧股骨远端骨折[J].中医正骨,2017,29(10):73.
[12]杜浩,田笑笑,郭丹,等.弹性髓内钉内固定治疗儿童股骨干骨折的疗效观察与并发症分析[J].中医正骨,2019,31(11):40.

备注/Memo

备注/Memo:
基金项目:浙江省中医药科技计划项目(2017ZA017) 通讯作者:盛红枫 E-mail:shenghongfeng123@163.com(收稿日期:2019-06-17 本文编辑:杨雅)
更新日期/Last Update: 2019-12-15